The public-private partnership aims to pump money into medical research as federal funds dry up. “We’re facing headwinds galore,” said Advocate’s chief innovation officer.
Advocate Health hopes new innovation center will boost medical research, training Read More »
The tool, which aims to help patients enroll in and maintain coverage, comes as healthcare braces for major cuts to the safety-net insurance program.
Medical billing firm Cedar launches Medicaid enrollment tool as cuts loom Read More »
Funds managed by Blackstone and TPG plan to acquire the medtech firm for up to $79 per share.
In this episode presented by Element Materials Technology, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney will explore how healthcare and pharmaceutical players are rethinking their strategies amid global supply chain disruption.
Cost Control to Capability Building: Rethinking Supply and Strategy in Pharma Read More »
The company’s technology, a modified herpes simplex virus used to deliver gene therapies, was given the FDA’s new designation based on its approved topical skin cream. What this will mean for Krystal’s still-in-development eye drop is unclear.
Krystal Biotech’s FDA Platform Designation Pushes Limits of the Award Read More »
The death occurred in a patient who had a complex medical background and who was being managed with several drugs, according to RBC Capital.
Ascendis Skids as FDA Detects Death in Patient on Yorvipath Read More »
In May, Summit released early data from the Phase III HARMONi study showing that while the PD-1/VEGF inhibitor resulted in significant progression-free survival improvements, it fell short of the overall survival bar.
Summit Eyes 2025 FDA Application for Ivonescimab Despite Overall Survival Miss Read More »
With data from the Phase III STELLAR-303 study in the books, Exelixis is plotting a 2025 regulatory application for zanzalintinib.
Galapagos at the start of the year had planned to split into two businesses, with one resulting entity focused on cell therapies. The biotech nixed these plans a few months later, instead choosing to put up for sale multiple cell therapy assets.
Galapagos Exits Cell Therapy, Cuts 365 Employees Read More »
La mayor parte del agua de la Tierra está en los océanos y es demasiado salada para poder beberla. Las plantas desalinizadoras pueden potabilizar el agua de mar, pero requieren grandes cantidades de energía. Ahora, unos científicos han desarrollado un material co …
Nuevo y barato sistema para desalinizar agua de mar Read More »
